August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
3 citations,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
16 citations,
January 2007 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” The document concludes that there are no reliable treatments for frontal fibrosing alopecia, with only temporary benefits from current options.
19 citations,
October 2008 in “Journal der Deutschen Dermatologischen Gesellschaft” Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
8 citations,
October 2018 in “Dermatologic Therapy” About 41% of Indian hair loss patients have low enzyme activity that affects hair loss treatment effectiveness, with men affected more than women. Testing for this can guide treatment.
November 2021 in “Frontiers in medicine” A patient with both bullous lichen planus and systemic lupus erythematosus showed improvement with treatment.
2 citations,
May 2018 in “Australasian Journal of Dermatology” Some patients' hair grew back black and white after chemotherapy.
278 citations,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
3 citations,
August 2021 in “Journal of Cosmetic Dermatology” Non-ablative Er:YAG laser effectively treats hair loss with high patient satisfaction and no side effects.